Insider Selling: Amedisys Inc (NASDAQ:AMED) Insider Sells 362 Shares of Stock

Share on StockTwits

Amedisys Inc (NASDAQ:AMED) insider Denise M. Bohnert sold 362 shares of Amedisys stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $220.00, for a total value of $79,640.00. Following the transaction, the insider now directly owns 9,095 shares of the company’s stock, valued at approximately $2,000,900. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ AMED opened at $234.16 on Friday. Amedisys Inc has a twelve month low of $121.00 and a twelve month high of $237.28. The company has a current ratio of 1.02, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 60.66, a price-to-earnings-growth ratio of 3.44 and a beta of 0.95. The business has a 50 day simple moving average of $202.10 and a 200-day simple moving average of $187.33.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.53. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. The business had revenue of $485.06 million during the quarter, compared to the consensus estimate of $468.38 million. During the same period in the previous year, the business earned $1.21 EPS. The business’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities analysts predict that Amedisys Inc will post 4.84 earnings per share for the current year.

Several research firms have recently issued reports on AMED. UBS Group cut their price target on Amedisys from $208.00 to $190.00 and set a “neutral” rating for the company in a research note on Monday, May 11th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $193.00 price objective for the company in a research report on Friday, May 1st. Raymond James lifted their price target on Amedisys from $210.00 to $255.00 and gave the company an “outperform” rating in a report on Thursday. Benchmark lifted their price target on Amedisys from $210.00 to $250.00 and gave the company a “buy” rating in a report on Thursday. Finally, Jefferies Financial Group lifted their price target on Amedisys from $225.00 to $250.00 and gave the company a “buy” rating in a report on Wednesday. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Amedisys presently has an average rating of “Buy” and an average price target of $215.67.

Several hedge funds and other institutional investors have recently modified their holdings of AMED. HMS Capital Management LLC purchased a new stake in shares of Amedisys during the second quarter valued at $750,000. Comerica Bank lifted its holdings in shares of Amedisys by 1.8% during the second quarter. Comerica Bank now owns 26,944 shares of the health services provider’s stock valued at $5,794,000 after purchasing an additional 483 shares during the last quarter. Shilanski & Associates Inc. lifted its holdings in shares of Amedisys by 2.0% during the second quarter. Shilanski & Associates Inc. now owns 4,967 shares of the health services provider’s stock valued at $986,000 after purchasing an additional 99 shares during the last quarter. UBS Group AG lifted its holdings in shares of Amedisys by 5.8% during the second quarter. UBS Group AG now owns 16,483 shares of the health services provider’s stock valued at $3,273,000 after purchasing an additional 903 shares during the last quarter. Finally, Landsberg Bennett & Dubbaneh LLC purchased a new stake in Amedisys in the 2nd quarter worth about $748,000. Institutional investors and hedge funds own 88.31% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Featured Article: What is the S&P/ASX 200 Index?

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Green Plains Partners LP  Short Interest Update
Green Plains Partners LP Short Interest Update
Short Interest in China Yuchai International Limited  Grows By 71.7%
Short Interest in China Yuchai International Limited Grows By 71.7%
Mark D. Hogan Buys 5,000 Shares of BCB Bancorp, Inc.  Stock
Mark D. Hogan Buys 5,000 Shares of BCB Bancorp, Inc. Stock
Insider Selling: Western Copper and Gold Corp  Senior Officer Sells C$47,400.00 in Stock
Insider Selling: Western Copper and Gold Corp Senior Officer Sells C$47,400.00 in Stock
Grigorios Siokas Sells 79,000 Shares of Cosmos Holdings Inc  Stock
Grigorios Siokas Sells 79,000 Shares of Cosmos Holdings Inc Stock
Insider Selling: Rimini Street Inc  President Sells 10,537 Shares of Stock
Insider Selling: Rimini Street Inc President Sells 10,537 Shares of Stock


© 2006-2020 Ticker Report